SUSAN HILSENBECK to Humans
This is a "connection" page, showing publications SUSAN HILSENBECK has written about Humans.
Connection Strength
0.799
-
A fully Bayesian latent variable model for integrative clustering analysis of multi-type omics data. Biostatistics. 2018 01 01; 19(1):71-86.
Score: 0.015
-
Making sense of clinical trial data: is inverse probability of censoring weighted analysis the answer to crossover bias? J Clin Oncol. 2012 Feb 01; 30(4):453-8.
Score: 0.010
-
To share or not to share: a randomized trial of consent for data sharing in genome research. Genet Med. 2011 Nov; 13(11):948-55.
Score: 0.010
-
Genetic testing and cancer risk management recommendations by physicians for at-risk relatives. Genet Med. 2011 Feb; 13(2):148-54.
Score: 0.009
-
Social networkers' attitudes toward direct-to-consumer personal genome testing. Am J Bioeth. 2009; 9(6-7):3-10.
Score: 0.008
-
Isolation of the ocular surface to treat dysfunctional tear syndrome associated with computer use. Ocul Surf. 2007 Oct; 5(4):308-15.
Score: 0.007
-
Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):1049s-1055s.
Score: 0.007
-
Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. Breast. 2005 Dec; 14(6):458-65.
Score: 0.007
-
Self-Collection for Cervical Cancer Screening in a Safety-Net Setting: The PRESTIS Randomized Clinical Trial. JAMA Intern Med. 2025 Sep 01; 185(9):1119-1127.
Score: 0.006
-
Evaluating the Implementation Success of an Intensity-Adapted Guideline for Pediatric Acute Myeloid Leukemia in Malawi: An Observational-Implementation Study Protocol. Pediatr Blood Cancer. 2025 Nov; 72(11):e32005.
Score: 0.006
-
A hybrid cloud data lake architecture supporting the integration of clinical and genomics data. Health Informatics J. 2025 Apr-Jun; 31(2):14604582251353440.
Score: 0.006
-
Real-world effectiveness of darolutamide in metastatic castration-resistant prostate cancer. Endocr Relat Cancer. 2025 Jun 01; 32(6).
Score: 0.006
-
A comprehensive atlas of AAV tropism in the mouse. Mol Ther. 2025 Mar 05; 33(3):1282-1299.
Score: 0.006
-
Hazard rates of recurrence following diagnosis of primary breast cancer. Breast Cancer Res Treat. 2005 Jan; 89(2):173-8.
Score: 0.006
-
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Mol Cancer Ther. 2024 Oct 01; 23(10):1494-1510.
Score: 0.006
-
Comparing the Diagnostic Yield of Germline Exome Versus Panel Sequencing in the Diverse Population of the Texas KidsCanSeq Pediatric Cancer Study. JCO Precis Oncol. 2024 Sep; 8:e2400187.
Score: 0.006
-
Gambian Mothers Lack Obstetric Danger Sign Knowledge, But Educational Intervention Shows Promise. Ann Glob Health. 2024; 90(1):31.
Score: 0.006
-
LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study. Lancet Oncol. 2024 Apr; 25(4):488-500.
Score: 0.006
-
The novel phosphatase NUDT5 is a critical regulator of triple-negative breast cancer growth. Breast Cancer Res. 2024 02 05; 26(1):23.
Score: 0.006
-
Targeting eIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer. J Clin Invest. 2023 12 15; 133(24).
Score: 0.006
-
Self-Sampling for Human Papillomavirus Testing: Acceptability in a U.S. Safety Net Health System. Am J Prev Med. 2024 03; 66(3):540-547.
Score: 0.006
-
A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer. Clin Cancer Res. 2023 08 15; 29(16):3101-3109.
Score: 0.006
-
Phase I / II trial of metformin as a chemo-radiosensitizer in a head and neck cancer patient population. Oral Oncol. 2023 10; 145:106536.
Score: 0.006
-
Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment. Cancer Res Commun. 2023 07; 3(7):1366-1377.
Score: 0.006
-
A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma. Clin Cancer Res. 2023 02 01; 29(3):548-559.
Score: 0.005
-
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. Nat Cancer. 2023 01; 4(1):128-147.
Score: 0.005
-
STAT5 confers lactogenic properties in breast tumorigenesis and restricts metastatic potential. Oncogene. 2022 11; 41(48):5214-5222.
Score: 0.005
-
Real-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium. Pediatr Blood Cancer. 2022 10; 69(10):e29812.
Score: 0.005
-
Endoscopic assessment of radiological stage IVA cervical cancer: A bivariate meta-analysis supporting an evidence-based staging algorithm proposal. Gynecol Oncol. 2022 06; 165(3):642-649.
Score: 0.005
-
Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics. Cancer Res Commun. 2021 12; 1(3):178-193.
Score: 0.005
-
Mouse-INtraDuctal (MIND): an in vivo model for studying the underlying mechanisms of DCIS malignancy. J Pathol. 2022 02; 256(2):186-201.
Score: 0.005
-
Targeting the Pro-survival Protein BCL-2 to Prevent Breast Cancer. Cancer Prev Res (Phila). 2022 01; 15(1):3-10.
Score: 0.005
-
Array-based gene expression profiling to study aging. Mech Ageing Dev. 2001 Jul 31; 122(10):999-1018.
Score: 0.005
-
A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop. Clin Cancer Res. 2021 10 15; 27(20):5472-5481.
Score: 0.005
-
A Wnt-Independent LGR4-EGFR Signaling Axis in Cancer Metastasis. Cancer Res. 2021 09 01; 81(17):4441-4454.
Score: 0.005
-
Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer. Clin Cancer Res. 2021 05 01; 27(9):2648-2662.
Score: 0.005
-
Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. Clin Cancer Res. 2021 09 01; 27(17):4870-4882.
Score: 0.005
-
Hormonal modulation of ESR1 mutant metastasis. Oncogene. 2021 02; 40(5):997-1011.
Score: 0.005
-
Mailed self-sample HPV testing kits to improve cervical cancer screening in a safety net health system: protocol for a hybrid effectiveness-implementation randomized controlled trial. Trials. 2020 Oct 21; 21(1):872.
Score: 0.005
-
Methylphenidate improves weight control in childhood brain tumor survivors with hypothalamic obesity. Pediatr Blood Cancer. 2020 07; 67(7):e28379.
Score: 0.004
-
Neurofibromin Is an Estrogen Receptor-a Transcriptional Co-repressor in Breast Cancer. Cancer Cell. 2020 03 16; 37(3):387-402.e7.
Score: 0.004
-
Outcomes Among Minority Patients With Metastatic Colorectal Cancer in a Safety-net Health Care System. Clin Colorectal Cancer. 2020 06; 19(2):e49-e57.
Score: 0.004
-
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. J Natl Cancer Inst. 2020 01 01; 112(1):46-54.
Score: 0.004
-
The Signaling Pathways Project, an integrated 'omics knowledgebase for mammalian cellular signaling pathways. Sci Data. 2019 10 31; 6(1):252.
Score: 0.004
-
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. Clin Cancer Res. 2020 02 15; 26(4):821-827.
Score: 0.004
-
Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy. Clin Cancer Res. 2020 02 01; 26(3):738-745.
Score: 0.004
-
Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer. Mol Cancer Res. 2019 11; 17(11):2318-2330.
Score: 0.004
-
Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia. Breast Cancer Res Treat. 2019 Sep; 177(2):427-435.
Score: 0.004
-
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. Ann Oncol. 2019 06 01; 30(6):927-933.
Score: 0.004
-
Measure once or twice -- does it really matter? J Natl Cancer Inst. 1999 Mar 17; 91(6):494-5.
Score: 0.004
-
Statistical analysis of array expression data as applied to the problem of tamoxifen resistance. J Natl Cancer Inst. 1999 Mar 03; 91(5):453-9.
Score: 0.004
-
Bacteria-to-Human Protein Networks Reveal Origins of Endogenous DNA Damage. Cell. 2019 01 10; 176(1-2):127-143.e24.
Score: 0.004
-
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance. Br J Cancer. 2019 02; 120(3):331-339.
Score: 0.004
-
Hypothyroidism after craniospinal irradiation with proton or photon therapy in patients with medulloblastoma. Pediatr Hematol Oncol. 2018 May; 35(4):257-267.
Score: 0.004
-
A prospective study of a simple algorithm to individually dose high-dose methotrexate for children with leukemia at risk for methotrexate toxicities. Cancer Chemother Pharmacol. 2019 02; 83(2):349-360.
Score: 0.004
-
Exome sequencing disclosures in pediatric cancer care: Patterns of communication among oncologists, genetic counselors, and parents. Patient Educ Couns. 2019 04; 102(4):680-686.
Score: 0.004
-
Biomarkers in benign breast disease: risk factors for breast cancer. J Natl Cancer Inst. 1998 Sep 02; 90(17):1247-8.
Score: 0.004
-
Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions. Breast Cancer Res. 2018 05 19; 20(1):42.
Score: 0.004
-
Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer. Nat Med. 2018 05; 24(4):505-511.
Score: 0.004
-
Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat. 1998; 52(1-3):227-37.
Score: 0.004
-
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res Treat. 2018 02; 167(3):731-740.
Score: 0.004
-
Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27. Clin Breast Cancer. 2018 02; 18(1):78-87.
Score: 0.004
-
CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study. Breast Cancer Res Treat. 2017 Nov; 166(1):277-287.
Score: 0.004
-
EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells. Nat Commun. 2017 06 12; 8:15773.
Score: 0.004
-
NEMO, a Transcriptional Target of Estrogen and Progesterone, Is Linked to Tumor Suppressor PML in Breast Cancer. Cancer Res. 2017 07 15; 77(14):3802-3813.
Score: 0.004
-
HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clin Cancer Res. 2017 Sep 01; 23(17):5123-5134.
Score: 0.004
-
Carbon nanotube capsules enhance the in vivo efficacy of cisplatin. Acta Biomater. 2017 08; 58:466-478.
Score: 0.004
-
Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients. Breast Cancer Res Treat. 1997 Apr; 43(2):153-63.
Score: 0.004
-
Retrospective review of genomic testing in breast cancer: Does it improve outcome? Breast Cancer Res Treat. 2017 May; 163(1):191-195.
Score: 0.004
-
Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial. JAMA. 2017 02 14; 317(6):596-605.
Score: 0.004
-
CELF1 is a central node in post-transcriptional regulatory programmes underlying EMT. Nat Commun. 2016 11 21; 7:13362.
Score: 0.004
-
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proc Natl Acad Sci U S A. 2016 10 25; 113(43):E6600-E6609.
Score: 0.003
-
Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes. Cancer Res. 2016 11 15; 76(22):6495-6506.
Score: 0.003
-
Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials. Clin Cancer Res. 2016 Sep 01; 22(17):4291-301.
Score: 0.003
-
Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion. Breast Cancer Res Treat. 2016 08; 158(3):441-54.
Score: 0.003
-
Stereotactic Biopsy of Segmental Breast Calcifications: Is Sampling of Anterior and Posterior Components Necessary? Acad Radiol. 2016 06; 23(6):682-6.
Score: 0.003
-
The SOX11 transcription factor is a critical regulator of basal-like breast cancer growth, invasion, and basal-like gene expression. Oncotarget. 2016 Mar 15; 7(11):13106-21.
Score: 0.003
-
Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. Mol Cancer Res. 2016 05; 14(5):470-81.
Score: 0.003
-
Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res. 1996 Mar; 2(3):585-92.
Score: 0.003
-
Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival. Cancer Res. 2016 04 01; 76(7):1942-53.
Score: 0.003
-
HER2 Signaling Drives DNA Anabolism and Proliferation through SRC-3 Phosphorylation and E2F1-Regulated Genes. Cancer Res. 2016 Mar 15; 76(6):1463-75.
Score: 0.003
-
Practical p-value adjustment for optimally selected cutpoints. Stat Med. 1996 Jan 15; 15(1):103-12.
Score: 0.003
-
An essential role for Ga(i2) in Smoothened-stimulated epithelial cell proliferation in the mammary gland. Sci Signal. 2015 Sep 15; 8(394):ra92.
Score: 0.003
-
Modernizing Eligibility Criteria for Molecularly Driven Trials. J Clin Oncol. 2015 Sep 01; 33(25):2815-20.
Score: 0.003
-
Wild-Type N-Ras, Overexpressed in Basal-like Breast Cancer, Promotes Tumor Formation by Inducing IL-8 Secretion via JAK2 Activation. Cell Rep. 2015 Jul 21; 12(3):511-24.
Score: 0.003
-
The Status of STAT3 and STAT5 in Human Breast Atypical Ductal Hyperplasia. PLoS One. 2015; 10(7):e0132214.
Score: 0.003
-
Expression of ERG protein in prostate cancer: variability and biological correlates. Endocr Relat Cancer. 2015 Jun; 22(3):277-87.
Score: 0.003
-
Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy. Clin Cancer Res. 2015 Sep 01; 21(17):3995-4003.
Score: 0.003
-
Cross-species identification of a plasma microRNA signature for detection, therapeutic monitoring, and prognosis in osteosarcoma. Cancer Med. 2015 Jul; 4(7):977-88.
Score: 0.003
-
Intratumoral heterogeneity in a Trp53-null mouse model of human breast cancer. Cancer Discov. 2015 May; 5(5):520-33.
Score: 0.003
-
Krt6a-positive mammary epithelial progenitors are not at increased vulnerability to tumorigenesis initiated by ErbB2. PLoS One. 2015; 10(1):e0117239.
Score: 0.003
-
Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. Breast Cancer Res. 2015 Jan 09; 17:3.
Score: 0.003
-
GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex. Proc Natl Acad Sci U S A. 2014 Dec 23; 111(51):18261-6.
Score: 0.003
-
Prognostic significance of insulin-like growth factor-binding protein expression in axillary lymph node-negative breast cancer. J Natl Cancer Inst. 1994 Dec 07; 86(23):1785-9.
Score: 0.003
-
A phase II trial of capecitabine concomitantly with whole-brain radiotherapy followed by capecitabine and sunitinib for brain metastases from breast cancer. Oncologist. 2015 Jan; 20(1):13.
Score: 0.003
-
The oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressor. Cell Rep. 2014 Nov 20; 9(4):1318-32.
Score: 0.003
-
STAT3 signaling is activated preferentially in tumor-initiating cells in claudin-low models of human breast cancer. Stem Cells. 2014 Oct; 32(10):2571-82.
Score: 0.003
-
AACR Cancer Progress Report 2014. Clin Cancer Res. 2014 Oct 01; 20(19 Suppl):S1-S112.
Score: 0.003
-
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Res. 2014 Sep 11; 16(5):430.
Score: 0.003
-
Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015 Apr 01; 21(7):1688-98.
Score: 0.003
-
Rising levels of estrogen receptor in breast cancer over 2 decades. Cancer. 1994 Sep 01; 74(5):1601-6.
Score: 0.003
-
Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers. Nat Commun. 2014 Aug 07; 5:4577.
Score: 0.003
-
An epigenomic approach to therapy for tamoxifen-resistant breast cancer. Cell Res. 2014 Jul; 24(7):809-19.
Score: 0.003
-
Pediatric data sharing in genomic research: attitudes and preferences of parents. Pediatrics. 2014 Apr; 133(4):690-7.
Score: 0.003
-
Agonistic induction of PPAR? reverses cigarette smoke-induced emphysema. J Clin Invest. 2014 Mar; 124(3):1371-81.
Score: 0.003
-
Effects of TP53 mutational status on gene expression patterns across 10 human cancer types. J Pathol. 2014 Apr; 232(5):522-33.
Score: 0.003
-
Pttg1/securin is required for the branching morphogenesis of the mammary gland and suppresses mammary tumorigenesis. Proc Natl Acad Sci U S A. 2014 Jan 21; 111(3):1008-13.
Score: 0.003
-
Amplification and over-expression of MAP3K3 gene in human breast cancer promotes formation and survival of breast cancer cells. J Pathol. 2014 Jan; 232(1):75-86.
Score: 0.003
-
Postoperative complications after thoracic and major abdominal surgery in patients with and without obstructive lung disease. Chest. 1993 Nov; 104(5):1445-51.
Score: 0.003
-
Semaphorin 4F as a critical regulator of neuroepithelial interactions and a biomarker of aggressive prostate cancer. Clin Cancer Res. 2013 Nov 15; 19(22):6101-11.
Score: 0.003
-
Participants' recall and understanding of genomic research and large-scale data sharing. J Empir Res Hum Res Ethics. 2013 Oct; 8(4):42-52.
Score: 0.003
-
Prognostic factors in lung cancer based on multivariate analysis. Am J Clin Oncol. 1993 Aug; 16(4):301-9.
Score: 0.003
-
Does formal instruction about the BI-RADS ultrasound lexicon result in improved appropriate use of the lexicon? AJR Am J Roentgenol. 2013 Aug; 201(2):456-61.
Score: 0.003
-
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res. 2013 Aug 01; 73(15):4885-97.
Score: 0.003
-
Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res. 2013 Jun 01; 73(11):3470-80.
Score: 0.003
-
Predictors of post-mastectomy reconstruction in an underserved population. J Plast Reconstr Aesthet Surg. 2013 Jun; 66(6):763-9.
Score: 0.003
-
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol. 2013 May 10; 31(14):1726-31.
Score: 0.003
-
Preclinical activity of taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells: comparison with taxol and conventional antineoplastic agents. Eur J Cancer. 1993; 29A(14):2009-14.
Score: 0.003
-
Surrogate endpoints in chemoprevention of breast cancer: guidelines for evaluation of new biomarkers. J Cell Biochem Suppl. 1993; 17G:205-11.
Score: 0.003
-
Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency. Breast Cancer Res. 2013; 15(5):R77.
Score: 0.003
-
Estimation of completeness and adjustment of age-specific and age-standardized incidence rates. Biometrics. 1992 Dec; 48(4):1249-62.
Score: 0.003
-
Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. Breast Cancer Res Treat. 2012 Dec; 136(3):795-804.
Score: 0.003
-
Elevated nuclear expression of the SMRT corepressor in breast cancer is associated with earlier tumor recurrence. Breast Cancer Res Treat. 2012 Nov; 136(1):253-65.
Score: 0.003
-
Selective small molecule Stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model. PLoS One. 2012; 7(8):e30207.
Score: 0.003
-
The increasing recognition of adenosquamous lung carcinoma (1977-1986). Am J Clin Oncol. 1992 Aug; 15(4):356-62.
Score: 0.003
-
BRCA1 promoter methylation status does not predict response to tamoxifen in sporadic breast cancer patients. Breast Cancer Res Treat. 2012 Aug; 135(1):135-43.
Score: 0.003
-
Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome. BMC Cancer. 2012 Jun 13; 12:243.
Score: 0.003
-
Improved methods of estimating mitotic activity in solid tumors. Hum Pathol. 1992 Jun; 23(6):601-2.
Score: 0.003
-
Ablation of steroid receptor coactivator-3 resembles the human CACT metabolic myopathy. Cell Metab. 2012 May 02; 15(5):752-63.
Score: 0.003
-
The prognostic significance of surgical staging for carcinoma of the endometrium. Gynecol Oncol. 1992 May; 45(2):142-6.
Score: 0.003
-
Cigarette smoke induction of osteopontin (SPP1) mediates T(H)17 inflammation in human and experimental emphysema. Sci Transl Med. 2012 Jan 18; 4(117):117ra9.
Score: 0.003
-
Why do so many prognostic factors fail to pan out? Breast Cancer Res Treat. 1992; 22(3):197-206.
Score: 0.002
-
Balancing the risks and benefits of genomic data sharing: genome research participants' perspectives. Public Health Genomics. 2012; 15(2):106-14.
Score: 0.002
-
A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science. 2012 Jan 20; 335(6066):348-53.
Score: 0.002
-
Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation. Breast Cancer Res. 2011; 13(6):R121.
Score: 0.002
-
Assessment of the learning curve for pancreaticoduodenectomy. Am J Surg. 2012 Jun; 203(6):684-90.
Score: 0.002
-
?1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. Breast Cancer Res. 2011 Aug 31; 13(4):R84.
Score: 0.002
-
A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer. Breast Cancer Res Treat. 2011 Oct; 129(3):819-27.
Score: 0.002
-
Meta-analysis of multiple microarray datasets reveals a common gene signature of metastasis in solid tumors. BMC Med Genomics. 2011 Jul 07; 4:56.
Score: 0.002
-
Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Proc Natl Acad Sci U S A. 2012 Feb 21; 109(8):2778-83.
Score: 0.002
-
Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth. Breast Cancer Res Treat. 2012 Feb; 132(1):61-73.
Score: 0.002
-
Keratin 6a marks mammary bipotential progenitor cells that can give rise to a unique tumor model resembling human normal-like breast cancer. Oncogene. 2011 Oct 27; 30(43):4399-409.
Score: 0.002
-
Significant differences among physician specialties in management recommendations of BRCA1 mutation carriers. Breast Cancer Res Treat. 2011 Aug; 129(1):221-7.
Score: 0.002
-
Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients. Clin Cancer Res. 2011 Jun 15; 17(12):4177-86.
Score: 0.002
-
Loss of Rho GDIa and resistance to tamoxifen via effects on estrogen receptor a. J Natl Cancer Inst. 2011 Apr 06; 103(7):538-52.
Score: 0.002
-
The p160 ER co-regulators predict outcome in ER negative breast cancer. Breast Cancer Res Treat. 2012 Jan; 131(2):463-72.
Score: 0.002
-
Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell. 2011 Mar 04; 144(5):703-18.
Score: 0.002
-
Long-term survival in stage III and IV ovarian cancer. Arch Gynecol Obstet. 1991; 249(2):87-93.
Score: 0.002
-
High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Clin Cancer Res. 2011 Apr 15; 17(8):2314-27.
Score: 0.002
-
Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts. Clin Cancer Res. 2011 Mar 15; 17(6):1351-61.
Score: 0.002
-
Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol. 2011 Jan 10; 29(2):166-73.
Score: 0.002
-
Thermal enhancement with optically activated gold nanoshells sensitizes breast cancer stem cells to radiation therapy. Sci Transl Med. 2010 Oct 27; 2(55):55ra79.
Score: 0.002
-
Hippo pathway effector Yap is an ovarian cancer oncogene. Cancer Res. 2010 Nov 01; 70(21):8517-25.
Score: 0.002
-
Drain data to predict clinically relevant pancreatic fistula. HPB (Oxford). 2010 Sep; 12(7):472-81.
Score: 0.002
-
Comparison of three tumor markers--CA-125, lipid-associated sialic acid (LSA), and NB/70K--in monitoring ovarian cancer. Gynecol Oncol. 1990 Aug; 38(2):181-6.
Score: 0.002
-
DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res Treat. 2010 Aug; 123(1):189-96.
Score: 0.002
-
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res. 2010; 12(3):R40.
Score: 0.002
-
Fibroblast growth factor receptor signaling dramatically accelerates tumorigenesis and enhances oncoprotein translation in the mouse mammary tumor virus-Wnt-1 mouse model of breast cancer. Cancer Res. 2010 Jun 15; 70(12):4868-79.
Score: 0.002
-
Value of pancreatic resection for cancer metastatic to the pancreas. J Surg Res. 2010 05 15; 160(2):268-76.
Score: 0.002
-
Segmental mastectomy without radiotherapy for T1 and small T2 breast carcinomas. Arch Surg. 1990 Mar; 125(3):364-9.
Score: 0.002
-
Quality control practices in centralized tumor registries in North America. J Clin Epidemiol. 1990; 43(11):1201-12.
Score: 0.002
-
Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer. Breast Cancer Res Treat. 2010 Oct; 123(3):651-60.
Score: 0.002
-
Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells. Cancer Res. 2009 Dec 01; 69(23):8853-61.
Score: 0.002
-
Genomic profiling of plasmablastic lymphoma using array comparative genomic hybridization (aCGH): revealing significant overlapping genomic lesions with diffuse large B-cell lymphoma. J Hematol Oncol. 2009 Nov 12; 2:47.
Score: 0.002
-
Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer. Clin Cancer Res. 2009 Oct 15; 15(20):6327-40.
Score: 0.002
-
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A. 2009 Aug 18; 106(33):13820-5.
Score: 0.002
-
Pharmacogenetics of breast cancer: toward the individualization of therapy. Cancer Invest. 2009 Aug; 27(7):699-703.
Score: 0.002
-
Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010 May; 121(1):1-11.
Score: 0.002
-
The efficacy of sertraline for controlling hot flashes in women with or at high risk of developing breast cancer. Breast Cancer Res Treat. 2009 Nov; 118(2):369-75.
Score: 0.002
-
Value of pancreatic resection for cancer metastatic to the pancreas. J Surg Res. 2009 Oct; 156(2):189-98.
Score: 0.002
-
Prevention of trauma/hemorrhagic shock-induced lung apoptosis by IL-6-mediated activation of Stat3. Clin Transl Sci. 2009 Feb; 2(1):41-9.
Score: 0.002
-
Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice. J Natl Cancer Inst. 2009 Jan 21; 101(2):107-13.
Score: 0.002
-
Low SAFB levels are associated with worse outcome in breast cancer patients. Breast Cancer Res Treat. 2010 Jun; 121(2):503-9.
Score: 0.002
-
GEMS (Gene Expression MetaSignatures), a Web resource for querying meta-analysis of expression microarray datasets: 17beta-estradiol in MCF-7 cells. Cancer Res. 2009 Jan 01; 69(1):23-6.
Score: 0.002
-
Gene expression in Barrett's esophagus: laser capture versus whole tissue. Scand J Gastroenterol. 2009; 44(7):787-95.
Score: 0.002
-
Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res. 2008 Sep 15; 68(18):7493-501.
Score: 0.002
-
Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol. 2008 Sep 01; 26(25):4078-85.
Score: 0.002
-
Early termination of a phase II clinical trial. Control Clin Trials. 1988 Sep; 9(3):177-88.
Score: 0.002
-
Cyclopamine inhibition of human breast cancer cell growth independent of Smoothened (Smo). Breast Cancer Res Treat. 2009 Jun; 115(3):505-21.
Score: 0.002
-
Clinical trial of high-dose oral medroxyprogesterone acetate in the treatment of metastatic breast cancer and review of the literature. Cancer. 1988 Jun 01; 61(11):2161-7.
Score: 0.002
-
Association of surgery with improved survival in stage IV breast cancer patients. Ann Surg. 2008 May; 247(5):732-8.
Score: 0.002
-
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008 May 07; 100(9):672-9.
Score: 0.002
-
Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat. 2009 Mar; 114(2):287-99.
Score: 0.002
-
Preoperative prediction of complete resection in pancreatic cancer. J Surg Res. 2008 Jun 15; 147(2):216-20.
Score: 0.002
-
Effect of BioGlue on the incidence of pancreatic fistula following pancreas resection. J Gastrointest Surg. 2008 May; 12(5):882-90.
Score: 0.002
-
The role of single nucleotide polymorphisms in breast cancer metastasis. Breast Cancer Res. 2008; 10(1):301.
Score: 0.002
-
The Rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative tumors in MMTV-erbB2 mice. Clin Cancer Res. 2007 Oct 15; 13(20):6224-31.
Score: 0.002
-
Association between the estrogen receptor alpha A908G mutation and outcomes in invasive breast cancer. Clin Cancer Res. 2007 Jun 01; 13(11):3235-43.
Score: 0.002
-
Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Res Treat. 2008 Mar; 108(2):233-40.
Score: 0.002
-
Constitutive activation of smoothened (SMO) in mammary glands of transgenic mice leads to increased proliferation, altered differentiation and ductal dysplasia. Development. 2007 Mar; 134(6):1231-42.
Score: 0.002
-
Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays. Cancer Res. 2006 Dec 15; 66(24):12009-18.
Score: 0.002
-
Wnt-1 is dominant over neu in specifying mammary tumor expression profiles. Technol Cancer Res Treat. 2006 Dec; 5(6):565-71.
Score: 0.002
-
The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol. 2006 Oct 01; 24(28):4611-9.
Score: 0.002
-
Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype. Clin Cancer Res. 2006 Sep 01; 12(17):5047-54.
Score: 0.002
-
Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer. 2006 Aug 15; 107(4):696-704.
Score: 0.002
-
Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res. 2006 Aug 15; 66(16):8266-73.
Score: 0.002
-
Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. Cancer Res. 2006 Jun 01; 66(11):5950-9.
Score: 0.002
-
Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance. Breast Cancer Res Treat. 2006 Feb; 95(3):229-33.
Score: 0.002
-
Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statement. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):997s-1000s.
Score: 0.002
-
Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):1013s-1018s.
Score: 0.002
-
Hormones, receptors, and growth in hyperplastic enlarged lobular units: early potential precursors of breast cancer. Breast Cancer Res. 2006; 8(1):R6.
Score: 0.002
-
Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers. Breast Cancer Res Treat. 2005 Dec; 94(3):279-84.
Score: 0.002
-
Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies. Breast Cancer Res Treat. 2006 Jan; 95(1):7-12.
Score: 0.002
-
cFos is critical for MCF-7 breast cancer cell growth. Oncogene. 2005 Sep 29; 24(43):6516-24.
Score: 0.002
-
Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J Clin Oncol. 2005 Jul 20; 23(21):4687-94.
Score: 0.002
-
The retinoid X receptor-selective retinoid, LGD1069, down-regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention. Cancer Res. 2005 Apr 15; 65(8):3462-9.
Score: 0.002
-
The promise of microarrays in the management and treatment of breast cancer. Breast Cancer Res. 2005; 7(3):100-4.
Score: 0.002
-
Research with stored biological samples: what do research participants want? Arch Intern Med. 2005 Mar 28; 165(6):652-5.
Score: 0.002
-
Genomic approaches in the management and treatment of breast cancer. Br J Cancer. 2005 Feb 28; 92(4):618-24.
Score: 0.002
-
Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol. 2005 Feb 20; 23(6):1169-77.
Score: 0.002
-
Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol. 2005 Apr 10; 23(11):2460-8.
Score: 0.002
-
Defining the role of raloxifene for the prevention of breast cancer. J Natl Cancer Inst. 2004 Dec 01; 96(23):1731-3.
Score: 0.002
-
Global gene expression analysis of estrogen receptor transcription factor cross talk in breast cancer: identification of estrogen-induced/activator protein-1-dependent genes. Mol Endocrinol. 2005 Feb; 19(2):362-78.
Score: 0.002
-
Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res. 2004 Apr 15; 10(8):2751-60.
Score: 0.001
-
Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst. 2003 Dec 17; 95(24):1825-33.
Score: 0.001
-
Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer. 2003 Dec; 4(5):348-53.
Score: 0.001
-
Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003 Aug 02; 362(9381):362-9.
Score: 0.001
-
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2003 Mar 05; 95(5):353-61.
Score: 0.001
-
Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood. 2003 May 15; 101(10):4078-87.
Score: 0.001
-
Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene. 2002 Oct 31; 21(50):7680-9.
Score: 0.001
-
Medical complications and outcomes after hip fracture repair. Arch Intern Med. 2002 Oct 14; 162(18):2053-7.
Score: 0.001
-
Sp1 is essential for estrogen receptor alpha gene transcription. J Steroid Biochem Mol Biol. 2002 Sep; 82(1):7-18.
Score: 0.001
-
BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol. 2002 Jun 01; 20(11):2701-12.
Score: 0.001
-
Mechanisms of hormonal prevention of breast cancer. Ann N Y Acad Sci. 2001 Dec; 952:23-35.
Score: 0.001
-
Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients. Clin Cancer Res. 2001 Jun; 7(6):1739-42.
Score: 0.001
-
AP-1 blockade inhibits the growth of normal and malignant breast cells. Oncogene. 2001 May 17; 20(22):2771-80.
Score: 0.001
-
Hsp27-induced MMP-9 expression is influenced by the Src tyrosine protein kinase yes. Biochem Biophys Res Commun. 2001 Mar 23; 282(1):186-93.
Score: 0.001
-
Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst. 2000 Dec 06; 92(23):1926-34.
Score: 0.001
-
Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model. Eur J Cancer. 2000 Dec; 36(18):2430-6.
Score: 0.001
-
Tacrolimus clearance is age-dependent within the pediatric population. Bone Marrow Transplant. 2000 Sep; 26(6):601-5.
Score: 0.001
-
A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res. 2000 Aug 01; 60(15):4026-9.
Score: 0.001
-
MGI 114: augmentation of antitumor activity when combined with topotecan. J Pediatr Hematol Oncol. 2000 Jul-Aug; 22(4):306-14.
Score: 0.001
-
Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients. J Clin Oncol. 2000 May; 18(9):1906-13.
Score: 0.001
-
Laparoscopic cholecystectomy and cirrhosis: a case-control study of outcomes. Liver Transpl. 2000 May; 6(3):340-4.
Score: 0.001
-
Prevalence of Cryptosporidium parvum infection in children along the Texas-Mexico border and associated risk factors. Am J Trop Med Hyg. 2000 May; 62(5):656-61.
Score: 0.001
-
Congenital anomalies and anthropometry of 42 individuals with deletions of chromosome 18q. Am J Med Genet. 1999 Aug 27; 85(5):455-62.
Score: 0.001
-
Loss of heterozygosity at D14S62 and metastatic potential of breast cancer. J Natl Cancer Inst. 1999 Aug 18; 91(16):1391-7.
Score: 0.001
-
The epidemiology of viral hepatitis in children in South Texas: increased prevalence of hepatitis A along the Texas-Mexico border. J Infect Dis. 1999 Aug; 180(2):509-13.
Score: 0.001
-
Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol. 1999 Aug; 17(8):2334-40.
Score: 0.001
-
Hsp27 overexpression inhibits doxorubicin-induced apoptosis in human breast cancer cells. Breast Cancer Res Treat. 1999 Jul; 56(2):187-96.
Score: 0.001
-
Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol. 1999 May; 13(5):787-96.
Score: 0.001
-
Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model. Cancer Res. 1999 Mar 01; 59(5):1049-53.
Score: 0.001
-
Significant activity of a novel cytotoxic agent, LY295501, against a wide range of tumors in the human tumor cloning system. Anticancer Drugs. 1999 Mar; 10(3):303-7.
Score: 0.001
-
Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft. Cancer Chemother Pharmacol. 1999; 43(5):402-8.
Score: 0.001
-
Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay. Cancer Chemother Pharmacol. 1999; 44(2):105-10.
Score: 0.001
-
Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells. Int J Oncol. 1998 Oct; 13(4):839-48.
Score: 0.001
-
A randomized trial of continuous or intermittent therapy with fluconazole for oropharyngeal candidiasis in HIV-infected patients: clinical outcomes and development of fluconazole resistance. Am J Med. 1998 Jul; 105(1):7-11.
Score: 0.001
-
Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy. J Clin Oncol. 1998 May; 16(5):1655-60.
Score: 0.001
-
Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A. 1998 Mar 17; 95(6):2920-5.
Score: 0.001
-
A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. Blood. 1998 Mar 01; 91(5):1533-41.
Score: 0.001
-
IGF system components as prognostic markers in breast cancer. Breast Cancer Res Treat. 1998 Feb; 47(3):295-302.
Score: 0.001
-
Immunofluorescence microscopy and flow cytometry characterization of chemical induction of latent Epstein-Barr virus. Clin Diagn Lab Immunol. 1998 Jan; 5(1):91-7.
Score: 0.001
-
A phase I and pharmacokinetic trial of terephthalamidine (NSC 57155) as a 120-hour continuous infusion. Invest New Drugs. 1998; 16(1):57-67.
Score: 0.001
-
Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer. Cancer Res. 1997 Dec 15; 57(24):5505-8.
Score: 0.001
-
Preclinical and clinical strategies for development of telomerase and telomere inhibitors. Ann Oncol. 1997 Nov; 8(11):1063-74.
Score: 0.001
-
Lack of prognostic value of cathepsin D levels for predicting short term outcomes of breast cancer patients. Cancer Lett. 1997 Jun 24; 116(2):177-83.
Score: 0.001
-
Preoperative spirometry and laparotomy: blowing away dollars. Chest. 1997 Jun; 111(6):1536-41.
Score: 0.001
-
Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice. Eur J Cancer. 1997 Jun; 33(7):1108-13.
Score: 0.001
-
WAF1/CIP1 protein expression in human breast tumors. Breast Cancer Res Treat. 1997 Apr; 43(2):99-103.
Score: 0.001
-
Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer. Invest New Drugs. 1997; 15(4):361-4.
Score: 0.001
-
The small heat shock protein hsp27 increases invasiveness but decreases motility of breast cancer cells. Invasion Metastasis. 1997; 17(3):113-23.
Score: 0.001
-
Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin Cancer Res. 1997 Jan; 3(1):103-9.
Score: 0.001
-
Multiple splicing variants of the estrogen receptor are present in individual human breast tumors. J Steroid Biochem Mol Biol. 1996 Nov; 59(3-4):251-60.
Score: 0.001
-
Risk of pulmonary complications after elective abdominal surgery. Chest. 1996 Sep; 110(3):744-50.
Score: 0.001
-
The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients. Clin Cancer Res. 1996 Jul; 2(7):1199-206.
Score: 0.001
-
Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: detection of higher levels in tumors with poor prognostic features. J Natl Cancer Inst. 1996 May 01; 88(9):601-6.
Score: 0.001
-
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol. 1996 Apr; 14(4):1128-35.
Score: 0.001
-
Signs of temporomandibular disorders in patients with horizontal mandibular deficiency. J Orofac Pain. 1996; 10(1):21-7.
Score: 0.001
-
Incidence and hospital stay for cardiac and pulmonary complications after abdominal surgery. J Gen Intern Med. 1995 Dec; 10(12):671-8.
Score: 0.001
-
Prognostic factors of early stage cervical cancer treated by radical hysterectomy. Cancer. 1995 Nov 15; 76(10 Suppl):1978-86.
Score: 0.001
-
Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol. 1995 Oct; 147(4):905-11.
Score: 0.001
-
p53 mutation and tamoxifen resistance in breast cancer. Clin Cancer Res. 1995 Oct; 1(10):1203-8.
Score: 0.001
-
Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst. 1995 May 17; 87(10):746-50.
Score: 0.001
-
Relationship of clone 4 estrogen receptor variant messenger RNA expression to some known prognostic variables in human breast cancer. Clin Cancer Res. 1995 Feb; 1(2):155-9.
Score: 0.001
-
Downregulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation. J Clin Invest. 1995 Jan; 95(1):167-71.
Score: 0.001
-
Inhibition of estrogen-induced breast cancer cell proliferation by reduction in autocrine transforming growth factor alpha expression. Cell Growth Differ. 1994 Dec; 5(12):1275-82.
Score: 0.001
-
Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units. Anticancer Drugs. 1994 Apr; 5(2):202-6.
Score: 0.001
-
Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. J Clin Oncol. 1994 Mar; 12(3):467-74.
Score: 0.001
-
Detection of insulin-like growth factor binding proteins (IGFBPs) by ligand blotting in breast cancer tissues. Cancer Lett. 1994 Feb 28; 77(1):25-32.
Score: 0.001
-
Prognostic factors: rationale and methods of analysis and integration. Breast Cancer Res Treat. 1994; 32(1):105-12.
Score: 0.001
-
Heat shock proteins and drug resistance. Breast Cancer Res Treat. 1994; 32(1):67-71.
Score: 0.001
-
p53 mutations in gastric and colorectal cancers in Texas Hispanics versus Anglos. Virchows Arch. 1994; 424(2):187-93.
Score: 0.001
-
Recombinant insulin-like growth factor binding protein-1 inhibits IGF-I, serum, and estrogen-dependent growth of MCF-7 human breast cancer cells. J Cell Physiol. 1993 Nov; 157(2):229-36.
Score: 0.001
-
Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol. 1993 Nov; 11(11):2194-204.
Score: 0.001
-
The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines. Cancer Res. 1993 Oct 01; 53(19):4443-8.
Score: 0.001
-
p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res. 1993 Jul 15; 53(14):3369-73.
Score: 0.001
-
Investigation of taxol as a potential radiation sensitizer. Cancer. 1993 Jun 01; 71(11):3774-8.
Score: 0.001
-
In vitro activity of the benzotriazine dioxide SR 4233 against human tumour colony-forming units. Eur J Cancer. 1993; 29A(3):423-5.
Score: 0.001
-
Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst. 1992 Dec 02; 84(23):1816-20.
Score: 0.001
-
Microinvasive carcinoma of the cervix. Cancer. 1992 Oct 15; 70(8):2121-8.
Score: 0.001
-
Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst. 1992 Oct 07; 84(19):1486-91.
Score: 0.001
-
Survival after first recurrence of breast cancer. The Miami experience. Cancer. 1992 Jul 01; 70(1):129-35.
Score: 0.001
-
Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs. 1992 Apr; 3(2):121-4.
Score: 0.001
-
Effects of recombinant human interleukin-1 alpha on clonogenic growth of primary human tumors in vitro. J Immunother (1991). 1992 Apr; 11(3):155-8.
Score: 0.001
-
Activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human tumor colony forming units. Anticancer Drugs. 1992 Apr; 3(2):143-6.
Score: 0.001
-
Optimal mastectomy timing. J Natl Cancer Inst. 1992 Mar 04; 84(5):346-8.
Score: 0.001
-
Preclinical activity of ilmofosine against human tumor colony forming units in vitro. Anticancer Drugs. 1992 Feb; 3(1):43-6.
Score: 0.001
-
A demonstration that breast cancer recurrence can be predicted by neural network analysis. Breast Cancer Res Treat. 1992; 21(1):47-53.
Score: 0.001
-
Making the most of your prognostic factors: presenting a more accurate survival model for breast cancer patients. Breast Cancer Res Treat. 1992; 22(3):251-62.
Score: 0.001
-
Five-drug antiemetic combination for cisplatin chemotherapy. Cancer Invest. 1992; 10(3):191-9.
Score: 0.001
-
Lung carcinoma in 1,336 patients. Am J Clin Oncol. 1991 Dec; 14(6):496-508.
Score: 0.001
-
Comparative efficacy of short-term versus long-term cefoxitin prophylaxis against postoperative infection after radical hysterectomy: a prospective study. Obstet Gynecol. 1991 May; 77(5):729-34.
Score: 0.001
-
Chemical enhancement of cisplatin cytotoxicity in a human ovarian and cervical cancer cell line. Gynecol Oncol. 1990 Sep; 38(3):315-22.
Score: 0.001
-
Reactive histiocytic hyperplasia with hemophagocytosis in hematopoietic organs: a reevaluation of the benign hemophagocytic proliferations. Hum Pathol. 1988 Jun; 19(6):705-12.
Score: 0.000
-
Toxicity of FED chemotherapy in non-small-cell lung cancer. Am J Clin Oncol. 1987 Dec; 10(6):499-506.
Score: 0.000
-
Cancer among Haitians in Florida. Cancer. 1987 Jan 01; 59(1):184-8.
Score: 0.000
-
Value of 8S/4S fractionation of estrogen receptors (ER) for prediction of response to hormonal manipulation in metastatic breast cancer. Breast Cancer Res Treat. 1984; 4(4):283-8.
Score: 0.000